Evidence map›Paper›PMID 39930023›Full record

ArticleScientific reports2025

Lifespan in rodents with MYT1L heterozygous mutation.

Allyson Schreiber, Raylynn G Swift, Leslie Wilson, Kristen L Kroll, Joseph D Dougherty, Susan E Maloney

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Allyson Schreiber *Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110-1093, USA.
Raylynn G Swift *Department of Psychiatry, Washington University School of Medicine, Campus Box 8232, 660 South Euclid Avenue, St. Louis, MO, 63110-1093, USA.
Leslie WilsonDivision of Comparative Medicine, Washington University School of Medicine, St. Louis, MO, 63110-1093, USA.
Kristen L KrollDepartment of Developmental Biology, Washington University School of Medicine, St. Louis, MO, 63110-1093, USA.
Joseph D DoughertyDepartment of Psychiatry, Washington University School of Medicine, Campus Box 8232, 660 South Euclid Avenue, St. Louis, MO, 63110-1093, USA.
Susan E MaloneyDepartment of Psychiatry, Washington University School of Medicine, Campus Box 8232, 660 South Euclid Avenue, St. Louis, MO, 63110-1093, USA. maloneys@wustl.edu.

Funding

WUIDDRC Supplement-Supporting the health and well-being of children with intellectual and developmental disability during COVID-19 pandemicP50HD103525 · NICHD · WASHINGTON UNIVERSITY · PI JEFFREY D MILBRANDT · 2020 to 2026
$15.5M
Training of the Pediatric Physician-ScientistT32HD043010 · NICHD · WASHINGTON UNIVERSITY · PI MARK E. LOWE · 2002 to 2026
$6.4M
Genomic and functional characterization of ASD and ID-associated MYT1L mutationR01MH124808 · NIMH · WASHINGTON UNIVERSITY · PI KROLL, KRISTEN L · 2021 to 2025
$3.7M
NICHD NIH HHS P50 HD103525NICHD NIH HHS T32 HD043010NIMH NIH HHS R01 MH124808NIMH NIH HHS R01MH124808
6 · The paper itself

Abstract

MYT1L syndrome is a newly recognized disorder characterized by intellectual disability, speech and motor delay, neuroendocrine disruptions, ADHD, and autism. In order to study this gene and its association with these phenotypes, our lab recently created a Myt1l heterozygous mutant mouse inspired by a clinically relevant mutation. This model recapitulates several of the physical and neurologic abnormalities seen in humans with MYT1L syndrome, such as weight gain, microcephaly, and behavioral disruptions. The majority of patients with this syndrome are young, and little is known about the impact of age on health and mortality in these patients. Using a Myt1l mutant mouse, we examined the impact of Myt1l mutation on body weights, lifespan, and histopathology findings of mice at the end of life. This cohort of heterozygous mice demonstrated increased body weight across the lifespan, however there was no significant difference in lifespan, apparent cause of death, or end of life histopathological findings between Myt1l heterozygous and wildtype mice. These findings suggest while Myt1l heterozygous mutation may influence overall brain development, it does not strongly impact other organ systems in the body over time.

Indexed as

Intellectual DisabilityLongevityMutationAnimalsBody WeightBrainDisease Models, AnimalFemaleHeterozygoteMaleMicePhenotypeLifespanMYT1L syndromeNeurodevelopmental disordersObesity

Identifiers

PMID39930023
PMCPMC11811182

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.